Jazz Pharmaceuticals (JAZZ) reported Q4 non-GAAP earnings late Tuesday of $6.60 per diluted share, up from $5.02 a year earlier.
Analysts polled by Capital IQ expected $5.81.
Revenue for the quarter ended Dec. 31 was $1.09 billion, up from $1.01 billion a year earlier.
Analysts surveyed by Capital IQ expected $1.06 billion.
For the full year 2025, the company expects diluted EPS of $22.50 to $24.00 on revenue of $4.15 billion to $4.40 billion. Analysts are looking for $22.03 and $4.32 billion, respectively.
Shares of Jazz Pharmaceuticals were down 2.6% in recent after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。